Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2010

01-04-2010 | Original Article

Aquaporin-2 Urinary Excretion in Cirrhosis: Relationship to Vasopressin and Nitric Oxide

Authors: Sook Hee Chung, Dae Won Jun, Kyung Tae Kim, Jeong Don Chae, Eun Kyoung Park, Byoung Kwan Son, Seong Hwan Kim, Yun Ju Jo, Young Sook Park

Published in: Digestive Diseases and Sciences | Issue 4/2010

Login to get access

Abstract

The aquaporin (AQP) water channel plays an important role in the regulation of water. AQP2 is expressed in the collection duct of the kidney, serving as the final channel that helps to regulate water excretion in the kidneys and affecting the regulation of water and hyponatremia in cirrhotic patients. So far, research on aquaporin expression in cirrhosis has had various results. The purpose of this study is to investigate the factors that affect the regulation of expression of AQP in patients with cirrhosis. The study comprised 81 cirrhosis patients and 18 control subjects. In each group, 24-h urine was collected and nitric oxide and vasopressin levels were measured in the blood. The amount of urinary AQP was measured by Western blot. In this study, the positivity rate and amount of expression of AQP was higher in the cirrhotic group than that of the control group. AQP expression in urine was also compared between the groups with use of diuretics and the groups with no use of diuretics. A 57.4% positivity was observed with the former, whereas a 51.5% was seen in the latter. No significance was found between the groups (P = 0.581). Expression of AQP in compensated cirrhotic patients is significantly higher than decompensated cirrhotic patients and is especially higher in cirrhotic patients with ascites than with no ascites. There is no relationship between the concentration of vasopressin and expression of AQP. Concentration of serum NOx is higher in cirrhotic patients than the control group and there is a positive association between the concentration of serum nitric oxide and AQP in urine. In conclusion, expression of AQP is increased in cirrhotic patients and is significantly higher in patients with ascites. There is a positive association between the expression of AQP and concentration of serum nitric oxide.
Literature
2.
go back to reference Albillos A, Rossi I, Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol. 1995;268:G459–G464.PubMed Albillos A, Rossi I, Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol. 1995;268:G459–G464.PubMed
3.
go back to reference Fujita N, Ishikawa SE, Sasaki S, et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol. 1995;269:F926–F931.PubMed Fujita N, Ishikawa SE, Sasaki S, et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol. 1995;269:F926–F931.PubMed
6.
go back to reference Jonassen TE, Nielsen S, Christensen S, Petersen JS. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis. Am J Physiol. 1998;275:F216–F225.PubMed Jonassen TE, Nielsen S, Christensen S, Petersen JS. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis. Am J Physiol. 1998;275:F216–F225.PubMed
8.
go back to reference Fernandez-Llama P. Aquaporins and renal water metabolism. Role in the physiopathology of water retention in cirrhosis. Gastroenterol Hepatol. 2001;24:205–209.PubMed Fernandez-Llama P. Aquaporins and renal water metabolism. Role in the physiopathology of water retention in cirrhosis. Gastroenterol Hepatol. 2001;24:205–209.PubMed
9.
go back to reference Fernandez-Llama P. Molecular bases for water/salt retention in experimental liver cirrhosis: aquaporins and renal sodium transporters. Nefrologia. 2002;22(Suppl 5):29–33.PubMed Fernandez-Llama P. Molecular bases for water/salt retention in experimental liver cirrhosis: aquaporins and renal sodium transporters. Nefrologia. 2002;22(Suppl 5):29–33.PubMed
12.
go back to reference Esteva-Font C, Baccaro ME, Fernandez-Llama P, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44:1555–1563. doi:10.1002/hep.21414.CrossRefPubMed Esteva-Font C, Baccaro ME, Fernandez-Llama P, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44:1555–1563. doi:10.​1002/​hep.​21414.CrossRefPubMed
13.
14.
20.
go back to reference Bouley R, Breton S, Sun T, et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin-2 in renal epithelial cells. J Clin Invest. 2000;106:1115–1126. doi:10.1172/JCI9594.CrossRefPubMed Bouley R, Breton S, Sun T, et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin-2 in renal epithelial cells. J Clin Invest. 2000;106:1115–1126. doi:10.​1172/​JCI9594.CrossRefPubMed
Metadata
Title
Aquaporin-2 Urinary Excretion in Cirrhosis: Relationship to Vasopressin and Nitric Oxide
Authors
Sook Hee Chung
Dae Won Jun
Kyung Tae Kim
Jeong Don Chae
Eun Kyoung Park
Byoung Kwan Son
Seong Hwan Kim
Yun Ju Jo
Young Sook Park
Publication date
01-04-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0829-x

Other articles of this Issue 4/2010

Digestive Diseases and Sciences 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine